Compare ETB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | KMDA |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.4M | 501.8M |
| IPO Year | 2004 | 2013 |
| Metric | ETB | KMDA |
|---|---|---|
| Price | $14.82 | $8.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 43.5K | ★ 67.7K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $7.99 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.03 | $5.54 |
| 52 Week High | $15.60 | $9.35 |
| Indicator | ETB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 47.13 |
| Support Level | $14.73 | $6.70 |
| Resistance Level | $15.04 | $8.88 |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 0.74 | 23.26 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.